Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression
Open accessAbstract
Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of immunoglobulin-secreting clonal plasma cells at the bone marrow (BM). The interaction between MM cells and the BM microenvironment, and specifically BM mesenchymal stem cells (BM-MSCs), has a key role in the pathophysiology of this disease. Multiple data support the idea that BM-MSCs not only enhance the proliferation and survival of MM cells but are also involved in the resistance of MM cells to certain drugs, aiding the progression of this hematological tumor. The relation of MM cells with the resident BM-MSCs is a two-way interaction. MM modulate the behavior of BM-MSCs altering their expression profile, proliferation rate, osteogenic potential, and expression of senescence markers. In turn, modified BM-MSCs can produce a set of cytokines that would modulate the BM microenvironment to favor disease progression. The interaction between MM cells and BM-MSCs can be mediated by the secretion of a variety of soluble factors and extracellular vesicles carrying microRNAs, long non-coding RNAs or other molecules. However, the communication between these two types of cells could also involve a direct physical interaction through adhesion molecules or tunneling nanotubes. Thus, understanding the way this communication works and developing strategies to interfere in the process, would preclude the expansion of the MM cells and might offer alternative treatments for this incurable disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mesenchymal stromal cells play a vital part in the aging and advancement of multiple myeloma by interacting with the tumor microenvironment, and their behavior can be influenced by myeloma cells, resulting in either supportive or inhibitory effects on tumor development.
“Mesenchymal stromal cells have been found to play a vital part in the aging and advancement of MM by interacting with the TME. These versatile precursor cells contribute significantly to regulating the TME. Importantly, their behavior can be influenced by MM cells, resulting in either supportive or inhibitory effects on tumor development [14, 262].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [14]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredThese alterations ended in notable modifications to the secretory profile and osteogenic differentiation capability of the BM-MSC, as a consequence of MM invasion in the BM niche.
“These alternations ended in notable modifications to the secretory profile and osteogenic differentiation capability of the BM-MSC, which is the consequence of the MM invasion in the BM niche [14].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [14]
The existence of MM cells within the BM niche modifies the activity of MSCs.
“The existence of MM cells within the BM niche modifies the activity of MSCs.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [14]
In MM disease status, after co-cultivating BM-MSCs, researchers have noticed a significant alteration in the expression of certain miRNAs in BM-MSCs.
“In the MM disease status, after co-cultivating BM-MSCs, researchers have noticed a significant alteration in the expression of certain microRNAs (miRNAs) in BM-MSCs.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Wu, Y. B., Zhang, Z., Wu, J., Hou, J., & Ding, G. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/3282860 · Cited by 11 · see citing works
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · see citing works
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277 · see citing works
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · see citing works
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846 · see citing works
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B. D., Terrian, D. M., Milella, M., Tafuri, A., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,285 · see citing works
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,453 · see citing works
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,293 · see citing works
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,235 · see citing works
Cunningham, B. A., Hemperly, J. J., Murray, B. A., Prediger, E. A., Brackenbury, R. W., & Edelman, G. M. (1987) · Science · doi:10.1126/science.3576199 · Cited by 1,117 · see citing works
Edelman, G. M. (1983) · Science · doi:10.1126/science.6823544 · Cited by 1,021 · see citing works
Matrix metalloproteinases and angiogenesis
Rundhaug, J. E. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00355.x · Cited by 962 · see citing works
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · see citing works
Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899 · see citing works
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
Roccaro, A. M., Sacco, A., Maiso, P., Azab, A. K., Tai, Y., Reagan, M. R., Azab, F., Flores, L. M., Campigotto, F., Weller, E. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66517 · Cited by 794 · see citing works
Osteoimmunology: evolving concepts in bone–immune interactions in health and disease
Tsukasaki, M., & Takayanagi, H. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0178-8 · Cited by 789 · see citing works
Structural basis of calcium-induced E-cadherin rigidification and dimerization
Nagar, B., Overduin, M., Ikura, M., & Rini, J. M. (1996) · Nature · doi:10.1038/380360a0 · Cited by 684 · see citing works
Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation
Park, J. H., Lee, N. K., & Lee, S. Y. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0225 · Cited by 679 · see citing works
The Intricate Role of CXCR4 in Cancer
Chatterjee, S., Azad, B. B., & Nimmagadda, S. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 674 · see citing works
Evidence for the Secretion of an Osteoclast Stimulating Factor in Myeloma
Mundy, G. R., Raisz, L. G., Cooper, R. A., Schechter, G. P., & Salmon, S. E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411142912001 · Cited by 670 · see citing works
Multiple Myeloma: Review of 869 Cases
Kyle, R. A. (1975) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)00115-6 · Cited by 644 · see citing works
Functional correlation between cell adhesive properties and some cell surface proteins.
Takeichi, M. (1977) · The Journal of Cell Biology · doi:10.1083/jcb.75.2.464 · Cited by 626 · see citing works
Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades
Hubbard, A. K., & Rothlein, R. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00223-9 · Cited by 594 · see citing works
Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.-T., Lin, B. K., Lentzsch, S., Davies, F. E., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 554 · see citing works
The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497 · see citing works
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y. M., Ngo, H. T., Runnels, J. M., Leleu, X. P., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T. K., Ghobrial, J. M., Jia, X., et al. (2006) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 479 · see citing works
Moschoi, R., Imbert, V., Nebout, M., Chiche, J., Mary, D. A. S. G., Prébet, T., Saland, E., Castellano, R., Pouyet, L., Collette, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-07-655860 · Cited by 467 · see citing works
Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R. L., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G. G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205664 · Cited by 463 · see citing works
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., Bruyne, E. D., Valckenborgh, E. V., Lahoutte, T., Wever, O. D., Vanderkerken, K., & Menu, E. (2014) · Blood · doi:10.1182/blood-2014-03-562439 · Cited by 443 · see citing works
Cell adhesion system and human cancer morphogenesis
Hirohashi, S., & Kanai, Y. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01485.x · Cited by 441 · see citing works
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0037-4 · Cited by 354 · see citing works
Hashizume, M., Hayakawa, N., & Mihara, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken363 · Cited by 345 · see citing works
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332 · see citing works
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307 · see citing works
Camp, B. V., Durie, B., Spier, C. M., Waele, M. D., Riet, I. V., Vela, E., Frutiger, Y. M., Richter, L., & Grogan, T. (1990) · Blood · doi:10.1182/blood.v76.2.377.377 · Cited by 306 · see citing works
Wnt Pathway in Bone Repair and Regeneration – What Do We Know So Far
Houschyar, K. S., Tapking, C., Borrelli, M. R., Popp, D., Duscher, D., Maan, Z. N., Chelliah, M. P., Li, J., Harati, K., Wallner, C., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00170 · Cited by 296 · see citing works
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 293 · see citing works
The Role of CD44 in Disease Pathophysiology and Targeted Treatment
Jordan, A. R., Racine, R. R., Hennig, M. J. P., & Lokeshwar, V. B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00182 · Cited by 272 · see citing works
Wang, J., Liu, X., Qiu, Y., Shi, Y. X., Cai, J., Wang, B., Wei, X., Ke, Q., Sui, X. Y., Wang, Y., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0554-z · Cited by 268 · see citing works
Gunn, W., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0220 · Cited by 260 · see citing works
Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J., & Alexandre, C. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115305 · Cited by 251 · see citing works
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238 · see citing works
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
Ridley, R., Xiao, H., Hata, H., Woodliff, J., Epstein, J., & Sanderson, R. D. (1993) · Blood · doi:10.1182/blood.v81.3.767.767 · Cited by 226 · see citing works
Oyajobi, B. O., Franchin, G., Williams, P. J., Pulkrabek, D., Gupta, A., Munoz, S. A., Grubbs, B. G., Zhao, M., Chen, D., Sherry, B. A., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3905 · Cited by 215 · see citing works
Tunneling nanotubes, an emerging intercellular communication route in development
Gerdes, H., Rustom, A., & Wang, X. (2012) · Mechanisms of Development · doi:10.1016/j.mod.2012.11.006 · Cited by 209 · see citing works
Samanta, D., & Almo, S. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1763-4 · Cited by 209 · see citing works
Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine
González-González, A., García‐Sánchez, D., Dotta, M., Rodríguez-Rey, J. C., & Pérez-Campo, F. M. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i12.1529 · Cited by 206 · see citing works
Self-citationGenomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C
Chilov, D., Kukk, E., Taira, S., Jeltsch, M., Kaukonen, J., Palotie, A. V., Joukov, V., & Alitalo, K. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25176 · Cited by 203 · see citing works
The art of cellular communication: tunneling nanotubes bridge the divide
Gurke, S., Barroso, J. F., & Gerdes, H. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0412-0 · Cited by 199 · see citing works
Polak, R., de Rooij, B., Pieters, R., & den Boer, M. L. (2015) · Blood · doi:10.1182/blood-2015-03-634238 · Cited by 183 · see citing works
The establishment of the plasma cell survival niche in the bone marrow
Chu, V. T., & Berek, C. (2012) · Immunological Reviews · doi:10.1111/imr.12011 · Cited by 175 · see citing works
Distinct calcium-independent and calcium-dependent adhesion systems of chicken embryo cells.
Brackenbury, R. W., Rutishauser, U. S., & Edelman, G. M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.387 · Cited by 175 · see citing works
Mitochondrial Transfer in Cancer: A Comprehensive Review
Zampieri, L. X., Silva‐Almeida, C., Rondeau, J. D., & Sonveaux, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063245 · Cited by 173 · see citing works
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168 · see citing works
Lokhorst, H. M., Lamme, T., Smet, M. D., Klein, S. C., de Weger, R. A., Oers, R. H. J. V., & Bloem, A. C. (1994) · Blood · doi:10.1182/blood.v84.7.2269.2269 · Cited by 159 · see citing works
Faict, S., Muller, J., Veirman, K. D., Bruyne, E. D., Maes, K., Vrancken, L., Heusschen, R., Raeve, H. D., Schots, R., Vanderkerken, K., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0139-7 · Cited by 155 · see citing works
CD138 mediates selection of mature plasma cells by regulating their survival
McCarron, M. J., Park, P. W., & Fooksman, D. (2017) · Blood · doi:10.1182/blood-2017-01-761643 · Cited by 150 · see citing works
Expression of VEGF and its receptors by myeloma cells
Kumar, S. K., Witzig, T. E., Timm, M., Haug, J., Wellik, L. E., Fonseca, R., Greipp, P. R., & Rajkumar, S. V. (2003) · Leukemia · doi:10.1038/sj.leu.2403084 · Cited by 150 · see citing works
Kumar, S. K., Witzig, T. E., Timm, M., Haug, J. L., Wellik, L. E., Kimlinger, T. K., Greipp, P. R., & Rajkumar, S. V. (2004) · Blood · doi:10.1182/blood-2003-11-3811 · Cited by 147 · see citing works
Pellat‐Deceunynck, C., Barillé‐Nion, S., Puthier, D., Rapp, M. J., Harousseau, J., Bataille, R., & Amiot, M. (1995) · PubMed · Cited by 146 · see citing works
Veirman, K. D., Wang, J., Xu, S., Leleu, X. P., Himpe, E., Maes, K., Bruyne, E. D., Valckenborgh, E. V., Vanderkerken, K., Menu, E., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.024 · Cited by 138 · see citing works
Li, B.-Z., Xu, H., Han, H., Song, S., Zhang, X., Ouyang, L., Qian, C., Hong, Y., Qiu, Y., Zhou, W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0359-0 · Cited by 136 · see citing works
Quirós-Roldán, E., Garcı́a-Pardo, A., & Brieva, J. A. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.6.1739 · Cited by 132 · see citing works
Kolba, M. D., Dudka, W., Zaręba-Kozioł, M., Kominek, A., Ronchi, P., Turos-Korgul, L., Chrościcki, P., Włodarczyk, J., Schwab, Y., Klejman, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2045-8 · Cited by 127 · see citing works
Adhesion molecules—The lifelines of multiple myeloma cells
Katz, B. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.04.003 · Cited by 111 · see citing works
Cell communication by tunneling nanotubes: Implications in disease and therapeutic applications
Mittal, R., Karhu, E., Wang, J., Delgado, S., Zukerman, R. J., Mittal, J., & Jhaveri, V. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27072 · Cited by 107 · see citing works
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Witzig, T. E., Moon‐Tasson, L. L., Dinarello, C. A., & Donovan, K. A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24352 · Cited by 92 · see citing works
Ahsmann, E., Lokhorst, H. M., Dekker, A. W., & Bloem, A. C. (1992) · Blood · doi:10.1182/blood.v79.8.2068.2068 · Cited by 91 · see citing works
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, V. G., & Kumar, S. K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 89 · see citing works
STAT3: A Promising Therapeutic Target in Multiple Myeloma
Chong, P. S. Y., Chng, W. J., & Mel, S. D. (2019) · Cancers · doi:10.3390/cancers11050731 · Cited by 89 · see citing works
Colla, S., Zhan, F., Xiong, W., Wu, X., Xu, H., Stephens, O., Yaccoby, S., Epstein, J., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-11-056747 · Cited by 89 · see citing works
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
Hengeveld, P. J., & Kersten, M. J. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.3 · Cited by 88 · see citing works
Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100
Clercq, E. D. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557054867075 · Cited by 87 · see citing works
The NF-κB Activating Pathways in Multiple Myeloma
Roy, P., Sarkar, U. A., & Basak, S. (2018) · Biomedicines · doi:10.3390/biomedicines6020059 · Cited by 85 · see citing works
Dewald, J. H., Colomb, F., Bobowski, M., Groux‐Degroote, S., & Delannoy, P. (2016) · Cells · doi:10.3390/cells5040043 · Cited by 84 · see citing works
Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease
Fu, J., Li, S., Feng, R., Ma, H., Sabeh, F., Roodman, G. D., Wang, J., Robinson, S. T., Guo, X.-D. E., Lund, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80276 · Cited by 76 · see citing works
Osteoblast function in myeloma
Roodman, G. D. (2010) · Bone · doi:10.1016/j.bone.2010.06.016 · Cited by 75 · see citing works
Cheng, Q., Li, X., Liu, J., Ye, Q., Chen, Y., Tan, S., & Liu, J. (2017) · Stem Cells International · doi:10.1155/2017/9012152 · Cited by 74 · see citing works
Lindquist, R. L., Niesner, R. A., & Hauser, A. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00788 · Cited by 74 · see citing works
Expression of adhesion molecules LFA‐3 and N‐CAM on normal and malignant human plasma cells
Barker, H. F., Hamilton, M. S., Ball, J., Drew, M., & FRANKLIN, I. M. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08236.x · Cited by 74 · see citing works
Raimondo, S., Urzì, O., Conigliaro, A., Bosco, G. L., Parisi, S., Carlisi, M., Siragusa, S. M., Raimondi, L., Luca, A. D., Giavaresi, G., et al. (2020) · Cancers · doi:10.3390/cancers12020449 · Cited by 72 · see citing works
Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease
Zhang, L., Lei, Q., Wang, H., Xu, C., Liu, T., Kong, F., Yang, C., Yan, G., Sun, L., Zhao, A., et al. (2018) · Theranostics · doi:10.7150/thno.27550 · Cited by 71 · see citing works
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70 · see citing works
Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 69 · see citing works
Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast
Reagan, M. R., Liaw, L., Rosen, C. J., & Ghobrial, I. M. (2015) · Bone · doi:10.1016/j.bone.2015.02.021 · Cited by 68 · see citing works
The microenvironment in myeloma
Lomas, O., Tahri, S., & Ghobrial, I. M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000615 · Cited by 68 · see citing works
Ria, R., Russo, F., Cirulli, T., Massaia, M., Tosi, P., Cavo, M., Guidolin, D., Ribatti, D., Dammacco, F., & Vacca, A. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-06-0334 · Cited by 66 · see citing works
Wang, J., Faict, S., Maes, K., Bruyne, E. D., Valckenborgh, E. V., Schots, R., Vanderkerken, K., & Menu, E. (2016) · Oncotarget · doi:10.18632/oncotarget.7792 · Cited by 65 · see citing works
Abe, M., Hiura, K., Ozaki, S., Kido, S., & Matsumoto, T. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0012-z · Cited by 65 · see citing works
The emerging role of exosomes in multiple myeloma
Moloudizargari, M., Abdollahi, M. R., Asghari, M. H., Zimța, A., Berindan‐Neagoe, I., & Nabavi, S. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100595 · Cited by 61 · see citing works
New Insights in Anti-Angiogenesis in Multiple Myeloma
Ribatti, D., & Vacca, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072031 · Cited by 61 · see citing works
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., & Chen, F.-M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt322 · Cited by 57 · see citing works
FOXM1 regulates glycolysis and energy production in multiple myeloma
Cheng, Y., Sun, F., Thornton, K. A., Jing, X., Dong, J., Yun, G., Pisano, M. D., Zhan, F., Kim, S. H., Katzenellenbogen, J. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02398-4 · Cited by 56 · see citing works
Liu, Z., Liu, H., Li, Y., Shao, Q., Chen, J., Song, J., & Fu, R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001010 · Cited by 55 · see citing works
García-Gómez, A., Rivas, J. D. L., Ocio, E. M., Dı́az-Rodrı́guez, E., Montero, J. C., Martín, M., Blanco, J. F., Sanchez-Guijo, F. M., Pandiella, A., Miguel, J. F. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2058 · Cited by 53 · see citing works
Mutational processes contributing to the development of multiple myeloma
Hoang, P. H., Cornish, A. J., Dobbins, S. E., Kaiser, M., & Houlston, R. S. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0221-9 · Cited by 53 · see citing works
Osteoblastogenesis and tumor growth in myeloma
Yaccoby, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903503438 · Cited by 52 · see citing works
Huang, N., Kawano, M., Harada, H., Harada, Y., Sakai, A., Kuramoto, A., & Niwa, O. (1993) · Blood · doi:10.1182/blood.v82.12.3721.3721 · Cited by 52 · see citing works
Notch signaling drives multiple myeloma induced osteoclastogenesis
Colombo, M., Thümmler, K., Mirandola, L., Garavelli, S., Todoerti, K., Apicella, L., Lazzari, E., Lancellotti, M., Platonova, N., Akbar, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2084 · Cited by 51 · see citing works
Berenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B., & Blau, I. W. (2015) · BMC Cancer · doi:10.1186/s12885-015-1078-3 · Cited by 44 · see citing works
Xiong, Y., Donovan, K. A., Kline, M. P., Gornet, M. K., Moon‐Tasson, L. L., Lacy, M. Q., Dispenzieri, A. A., Gertz, M. A., Greipp, P. R., & Lust, J. A. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.83 · Cited by 43 · see citing works
Hale, J. S., Li, M., & Lathia, J. D. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.21294 · Cited by 42 · see citing works
Visram, A., Dasari, S., Anderson, E., Kumar, S. K., & Kourelis, T. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00440-4 · Cited by 41 · see citing works
Targeting SDF-1 in multiple myeloma tumor microenvironment
Bouyssou, J., Ghobrial, I. M., & Roccaro, A. M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.028 · Cited by 41 · see citing works
Berenstein, R., Nogai, A., Wächter, M., Blau, O., Kühnel, A., Schmidt‐Hieber, M., Kunitz, A., Pezzutto, A., Dörken, B., & Blau, I. W. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22440 · Cited by 40 · see citing works
Terpos, E., Anargyrou, K., Katodritou, E., Kastritis, E., Παπαθεοδώρου, Α., Christoulas, D., Pouli, A. G., Michalis, E., Delimpasi, S., Gkotzamanidou, M. A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26062 · Cited by 38 · see citing works
Adhesion Molecules in Multiple Myeloma Oncogenesis and Targeted Therapy
Zerdan, M. B., Nasr, L. F., Kassab, J. T., Saba, L., Ghossein, M., Yaghi, M., Dominguez, B. G., & Chaulagain, C. P. (2022) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2021-0017 · Cited by 37 · see citing works
Huang, N., Kawano, M., Mahmoud, M., Mihara, K., Tsujimoto, T., Niwa, O., & Kuramoto, A. (1995) · Blood · doi:10.1182/blood.v85.12.3704.bloodjournal85123704 · Cited by 35 · see citing works
Umezu, T., Imanishi, S., Yoshizawa, S., Kawana, C., Ohyashiki, J. H., & Ohyashiki, K. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000403 · Cited by 34 · see citing works
Pathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33 · see citing works
Gao, X., Zhou, J., Wang, J., Dong, X., Chang, Y., & Jin, Y. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02793-9 · Cited by 31 · see citing works
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing
Moschetta, M., Kawano, Y., Sacco, A., Belotti, A., Ribolla, R., Chiarini, M., Giustini, V., Bertoli, D., Sottini, A., Valotti, M., et al. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0399-3 · Cited by 29 · see citing works
Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma
Sherbenou, D. W., Yang, S., Behrens, C. R., Aftab, B. T., de Acha, O. P., Murnane, M., Bearrows, S. C., Hann, B. C., Wolf, J. L., Martin, T. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0400 · Cited by 29 · see citing works
Zhang, X.-H., Sun, Y., Wang, Z.-Y., Huang, Z.-P., Li, B.-Z., & Fu, J.-X. (2015) · Leukemia and Lymphoma · doi:10.3109/10428194.2014.913289 · Cited by 28 · see citing works
Gu, J., Wang, M., Wang, X., Li, J., Liu, H., Lin, Z., Yang, X., Zhang, X., & Liu, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.862524 · Cited by 27 · see citing works
Bone Marrow Stromal Cells Drive Key Hallmarks of B Cell Malignancies
Mangolini, M., & Ringshausen, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041466 · Cited by 26 · see citing works
Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis
de Rooij, B., Polak, R., van den Berk, L. C. J., Stalpers, F., Pieters, R., & den Boer, M. L. (2017) · Haematologica · doi:10.3324/haematol.2016.159517 · Cited by 25 · see citing works
Yamamoto, C., Minakata, D., Koyama, S., Sekiguchi, K., Fukui, Y., Murahashi, R., Nakashima, H., Matsuoka, S., Ikeda, T., Kawaguchi, S., et al. (2022) · Blood · doi:10.1182/blood.2021015220 · Cited by 25 · see citing works
Production of fibronectin and adherence to fibronectin by human myeloma cell lines
Riet, I. V., Greef, C. D., del Favero, H., Demanet, C. J., & Camp, B. V. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04907.x · Cited by 24 · see citing works
Klimienė, I., Radzevičius, M., Matuzevičienė, R., SINKEVIČ, K., Kučinskienė, Z. A., & Pečeliūnas, V. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13387 · Cited by 22 · see citing works
Dun, X., Jiang, H., Zou, J., Shi, J., Zhou, L., Zhu, R., & Hou, J. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-247 · Cited by 22 · see citing works
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032645 · Cited by 20 · see citing works
Andersen, N. F., Kristensen, I. B., Preiss, B., Christensen, J. H., & Abildgaard, N. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12473 · Cited by 20 · see citing works
Selective in vivo growth of lymphocyte function- associated antigen-1–positive murine myeloma cells
Asosingh, K., Vankerkhove, V., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)00970-0 · Cited by 18 · see citing works
Do human myeloma cells directly produce basic FGF?
Colla, S., Morandi, F., Lazzaretti, M., Polistena, P., Svaldi, M., Coser, P., Bonomini, S., Hojden, M., Martella, E. M., Chisesi, T., et al. (2003) · Blood · doi:10.1182/blood-2003-06-1883 · Cited by 17 · see citing works
Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma
Suzuki, R., Ogiya, D., Ogawa, Y., Kawada, H., & Ando, K. (2022) · Current Oncology · doi:10.3390/curroncol29110672 · Cited by 12 · see citing works
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?
D’Agostino, M., Mina, R., & Gay, F. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30254-6 · Cited by 12 · see citing works
Goodarzi, A., Valikhani, M., Amiri, F., & Safari, A. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00822-6 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy
Wang, Y.-M., Vandewalle, N., Veirman, K. D., Vanderkerken, K., Menu, E., & Bruyne, E. D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01699-3 · Cited by 29 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 16 · see citing works
Piperigkou, Z., Mangani, S., Koletsis, N. E., Koutsakis, C., MASTRONIKOLIS, N. S., Franchi, M., & Karamanos, N. K. (2025) · FEBS Journal · doi:10.1111/febs.70207 · Cited by 15 · see citing works
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., & Cavo, M. (2024) · Cancers · doi:10.3390/cancers16132337 · Cited by 12 · see citing works
Long, S., Long, S., He, H., Luo, L., Liu, M., & Ding, T. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04399-9 · Cited by 11 · see citing works
Zhang, C., Li, D., Zhang, X., Dai, R., Kang, W., Li, Y., Liu, Q., Gao, M., Zheng, Z., Zhang, R., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101054 · Cited by 11 · see citing works
García-Briega, M. I., Plá-Salom, J., Trujillo, S. C., Tolosa, L., Cordón, L., Sempere, A., & Ribelles, J. L. G. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214243 · Cited by 10 · see citing works
Sutanto, H., Sandra, D. Y., Safira, A., Adytia, G. J., Waitupu, A., & Romadhon, P. Z. (2025) · Medical Oncology · doi:10.1007/s12032-025-02807-0 · Cited by 11 · see citing works
Ilić, J., Koelbl, C., Simon, F., Wußmann, M., Ebert, R., Trivanović, D. I., & Herrmann, M. (2024) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2023.0374 · Cited by 7 · see citing works
Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy
Fu, C., Zhai, Y., Yan, L., Jin, S. L., Shang, J., Shi, X., & Wu, D. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003655 · Cited by 7 · see citing works
Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy
Zhao, X., Ming, X., Wu, J., Zhu, X., & Xiao, Y. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11011-6 · Cited by 7 · see citing works
Walid, M., Saboor, M., Haque, S., & Mohammad, M. G. (2026) · Blood Science · doi:10.1097/bs9.0000000000000270 · Cited by 6 · see citing works
Song, Y., Guo, N., Zi, F., Zheng, J., & Cheng, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113080 · Cited by 6 · see citing works
Zhu, L., Nawaz, M. A., Zuo, Y., & Zeng, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104913 · Cited by 5 · see citing works
Exosomal microRNAs (miRNAs) in blood and urine under physiological conditions: a comparative study
Chun-yan, L., Yuan, Z., & Yao, H. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e6 · Cited by 4 · see citing works
Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target
Komemi, O., Orbuch, E., Jarchowsky-Dolberg, O., Brin, Y. S., Tartakover‐Matalon, S., Pasmanik‐Chor, M., Lishner, M., & Drucker, L. (2025) · Oncogenesis · doi:10.1038/s41389-025-00554-5 · Cited by 4 · see citing works
Li, Y., Liu, Y., Yang, X., Yang, B., Yang, B., Chen, J., Chen, J., Yuan, X., Xu, X., Liu, G., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04222-8 · Cited by 3 · see citing works
Jin, Y., Yue, Y., Li, Q., Tang, K., Mao, Y., Wang, K., & Zhang, A. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115369 · Cited by 2 · see citing works
Mondal, S., Becker, N. J., Huo, Y., Zhang, P., Johnson, T. S., Landgren, O., Coffey, D. G., Walker, B. A., & Liu, E. (2026) · Biomedicines · doi:10.3390/biomedicines14071556 · Cited by 2 · see citing works
Phenotypic and functional alterations of bone marrow MSCs exposed to multiple myeloma cells
Kim, H. J., Eom, S. Y., Hwang, S., Kim, H., Won, J., Chung, S. H., & Yahng, S. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00415-5 · Cited by 2 · see citing works
Aydemir, D. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2026.1686097 · Cited by 1 · see citing works
Chen, H., Ren, H., Wang, X. W., Liu, C., Jiang, L., Zang, S., Liu, T., Wang, S., Huang, W., & Zhou, L. (2026) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2026.102073 · Cited by 1 · see citing works
Huo, Y., Mao, Y., Luo, F., Zhang, F., Xie, L., Zhang, X., Liu, K., Sun, L., Liu, H., Song, L., et al. (2023) · Journal of Clinical and Nursing Research · doi:10.26689/jcnr.v7i4.5139
Exploring Oncogenic Factors Influence on Multiple Myeloma Progression and Patient Survival
Muhammad, Z. K., Khan, A. A., Ibrar, M. K., Gao, F., Ping, Z., & Muhammad, Z. (2024) · Diseases & Research · doi:10.54457/dr.202402001
Kerna, N. A., Pruitt, K. D., Carsrud, N. D. V., Ngwu, D. C., Kadivi, K., Holets, H. M., Flores, J. V., Alozie, U. G., Senat, A. J. B., Azi, C. I., et al. (2024) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2024.2(5).02
Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study
Wu, H., Sun, H., Wang, Y., Lv, Z., Li, Y., Su, F., Liu, C., Chen, Y., Shi, K., Zhao, P., et al. (2025) · doi:10.69638/jmmr20210110x
An, S., Park, Y., Mora, C., Sweiss, K. I., Uzoka, C. C., Sanchez, M. E., Zucchetti, E., Campbell‐Lee, S. A., Ma, W., Chen, Z., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.09.010
Stroe-Ionescu, A.-Ş., Boldeanu, L., Pătraşcu, A. M., Goanta, J. G., Siloşi, I., Assani, M.-Z., Rotaru, I., Tanase, A. D., & Boldeanu, M. V. (2026) · Biomedicines · doi:10.3390/biomedicines14081839
Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities
Hussain, A., Moniot, J., Sumaya, M., & Hughes, D. (2026) · Cureus · doi:10.7759/cureus.115585
Topalova, L., Stoyanova, T., García-Parra, N., Ribelles, J. L. G., Todinova, S. J., & Altankov, G. (2026) · Cells · doi:10.3390/cells15191775
Sitzia, C., Manferdini, C., D’Atri, G., Lisignoli, G., Dessena, M., Giuliani, N., & Storti, P. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1954766
- Authors
- García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M.
- Affiliations
- Universidad de Cantabria (ES)
- Corresponding author
- Pérez-Campo, Flor M
- Venue
- World Journal of Stem Cells
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2023-05-26
- Volume
- 15
- Issue
- 5
- Pages
- 421-437
- ISSN
- 1948-0210 (ISSN-L)
- PMC
- PMC10277973
- OpenAlex
- W4378212829
- Cited by
- 32
- References
- 129
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 9 · 2023: 3
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Stem Cells (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by-nc)
- Funders
- Universidad de Cantabria
- Instituto de Investigación Marqués de Valdecilla
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- multiple myeloma, bone marrow mesenchymal stem cells, tumor microenvironment, intercellular communication, drug resistance, extracellular vesicles, microRNA, long non-coding RNA, tunneling nanotubes, osteogenic differentiation, cellular senescence, cytokines, disease progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
